1Gum PA,Kottke-Marchant K,Poggio ED,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88(3):230-235. 被引量：1
2Kuliczkowski W,Witkowski A,Polonski L,et al.Interindividual variability in the response to oral antiplatelet drugs:a position paper of the working group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society,endorsed by the working group on Thrombosis of the European Society of Cardiology[J].Eur Heart,2009,30(4):426-435. 被引量：1
3O'Donnell C J,Larson MG,Feng D,et al.Genetic and environmental contributions to platelet aggregation:the Framingham heart study[J].Circulation,2001,103(25):3051-3056. 被引量：1
4Faraday N,Yanek LR,Mathias R,et al.Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1[J].Circulation,2007,115(19):2490-2496. 被引量：1
6Gonzalez-Conejero R,Rivera J,Corral J,et al.Biological assessment of aspirin efficacy on healthy individuals:heterogeneous response or aspirin failure?[J].Stroke,2005,36(2):276-280. 被引量：1
7Hillarp A,Palmqvist B,Lethagen S,et al.Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke[J].Thromb Res,2003,112(5-6):275-283. 被引量：1
8Takahashi S,Ushida M,Komine R,et al.Platelet responsiveness to in vitro aspirin is independent of COX-1and COX-2 protein levels and polymorphisms[J].Thromb Res,2008,121(4):509-517. 被引量：1
9Li Q,Chen BL,Ozdemir V,et al.Frequency of genetic polymorphisms of COX1,GPⅢa and P2Y1 in a Chinese population and association with attenuated response to aspirin[J].Pharmacogenomics,2007,8(6):577-586. 被引量：1
2Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1 [J]. Circulation, 2007, 115(19):2490-2496. 被引量：1
3Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin [J]. J Thromb Haemost, 2005, 3(10):2340-2345. 被引量：1
4Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? [J]. Stroke, 2005, 36(2):276-280. 被引量：1
5Hillarp A, Palmqvist B, Lethagen S, et al. Mutations within the cyclooxygenase-1 gene in aspirin non- responders with recurrence of stroke [J]. Thromb Res, 2003, 112(5-6):275-283. 被引量：1
6Takahashi S, Ushida M, Komine R, et al. Platelet responsiveness to in vitro aspirin is independent of COX- 1 and COX-2 protein levels and polymorphisms [J]. Thromb Res, 2008, 121(4): 509-517. 被引量：1
7Li Q, Chen BL, Ozdemir V, et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin[J]. Pharmacogenomics, 2007, 8(6):577-586. 被引量：1
9Dropinski J, Musial J, Sanak M, et al. Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease[J]. Thromb Res, 2007, 119(3):301-303. 被引量：1
10Goodman T. Ferro A, Sharma P, et al. Pharmacogenetics of aspirin resistance: a comprehensive systematic review [J]. Br J Clin Pharmacol, 2008,66(2): 222-232. 被引量：1
5Karen L. Furie,Scott E. Kasner,Robert J. Adams,Gregory W. Albers,Ruth L. Bush,Susan C. Fagan,Jonathan L. Halperin,S. Claiborne Johnston,Irene Katzan,Walter N. Kernan,Pamela H. Mitchell,Bruce Ovbiagele,Yuko Y. Palesch,Ralph L. Sacco,Lee H. Schwamm,Sylvia Wassertheil-Smoller,Tanya N. Turan,Deidre Wentworth,李海峰(译),刘涛(译),杨潘(译),王鹏(译).卒中或短暂性脑缺血发作患者的卒中预防指南 美国心脏协会／美国卒中协会为医疗卫生专业人员制定的指南[J].国际脑血管病杂志,2011,19(1):1-49. 被引量：392
